News NFL Biosciences

Stocks

ALNFL

FR0014003XT0

Biotechnology & Medical Research

Market Closed - Euronext Paris 11:55:00 2026-10-14 EDT			5-day change	1st Jan Change
0.5830 ^EUR	+0.87%		-10.86%	-50.51%

10-06	NFL Biosciences Provides Progress Update on NFL-101 and NFL-102 Clinical Programs in Smoking Cessation	CI
07-28	NFL Biosciences Submits Application For Authorization Of The Phase 2 Tonic Clinical Trial Evaluating NFL-102 In Smoking Cessation	CI

All News

Mentions Relevance

10-06	NFL Biosciences: Progress Update Ahead of Upcoming Value-Creating Milestones for Its Two Clinical Programs in Smoking Cessation	BU
10-06	NFL Biosciences Provides Progress Update on NFL-101 and NFL-102 Clinical Programs in Smoking Cessation	CI
09-08	NFL Biosciences to Present Its Personalized Medicine Approach to Smoking Cessation at the 20th Congress of the Société Francophone de Tabacologie	BU
07-28	NFL Biosciences Submits an Application for Authorization of the Phase 2 TONIC Clinical Trial Evaluating NFL-102 in Smoking Cessation	BU
07-28	NFL Biosciences Submits Application For Authorization Of The Phase 2 Tonic Clinical Trial Evaluating NFL-102 In Smoking Cessation	CI
07-07	Nfl Biosciences Presents Three Scientific Communications on Nfl-101 and Nfl-102 At 2026 Srnt-Europe Conference	CI
07-07	International Scientific Recognition for NFL Biosciences: 3 Presentations Selected at the 2026 SRNT-Europe Conference, Including an Oral Presentation on NFL-102	BU
06-30	NFL Biosciences Successfully Manufactures GMP Clinical Batch Of NFL-102 And Validates Industrial Production Chain	CI
06-30	NFL Biosciences validates industrial-scale production of NFL-102 for smoking cessation
06-30	NFL Biosciences Announces the Successful Manufacturing of a GMP Clinical Batch of NFL-102 and Validates Its Industrial Production Chain	BU
06-01	NFL Biosciences Releases New Results on NFL-101 and Reaffirms Its Personalized Approach to Smoking Cessation	CI
06-01	NFL Biosciences validates breakthrough in personalized medicine
06-01	NFL Biosciences Releases New Results on NFL-101 and Reaffirms Its Personalized Approach to Smoking Cessation	BU
05-26	NFL Biosciences to File Patent Application for Smoking Cessation Drug-linked Biomarker	MT
05-25	NFL Biosciences files new patent application
05-25	NFL Biosciences Is Strengthening Its Personalized Medicine Approach to Smoking Cessation With a New Patent Application	BU
05-25	NFL Biosciences Files Patent Application Protecting Predictive Efficacy Biomarker Associated With NFL-101	CI
05-11	NFL Biosciences SA Clarifies Objectives And Evaluation Criteria For Predictive Biomarker Associated With NFL-101	CI
05-11	NFL Biosciences Clarifies the Objectives and Evaluation Criteria for a Predictive Biomarker Associated With NFL-101	BU
05-04	NFL Biosciences: International Scientific Community’s Interest in NFL-102 for Smoking Cessation Confirmed by the Selection of Its Work at Two Leading Conferences	BU
05-04	NFL Biosciences Presents Work On NFL-102 For Smoking Cessation At International Scientific Conferences	CI
04-15	NFL Biosciences SA Reports Earnings Results for the Full Year Ended December 31, 2025	CI
04-15	NFL Biosciences Presents Its 2025 Annual Results and Provides an Update on Its Clinical Progress Driven by a New Paradigm in Smoking Cessation	BU
04-15	NFL Biosciences Strengthens Its Cash Position by €2.6 Million Through Bond Financing Subscribed by a Group of European Institutional Investors	BU
04-14	NFL Biosciences SA announced that it expects to receive ?2.6 million in funding from Vester Finance	CI